We previously showed that men with MHI are 20% less likely to be diagnosed with PC, but when diagnosed, are nearly 2 times more likely to have aggressive PC compared to non-MHI men (Klaassen et al. ASCO 2023). It is unknown whether men with MHI and PC receive definitive Tx (DTx) and have comparable post-Tx outcomes to non-MHI men with PC. This study assessed (i) receipt of DTx, (ii) adherence to surveillance (surv) after Tx, and (iii) biochemical recurrence (BCR) rates among MHI vs non-MHI men.
Methods:
This national, retrospective study used a matched cohort of male veterans who were diagnosed with PC following recent MHI Dx (within 3 yrs prior to PC Dx) or diagnosed with PC in the absence of MHI from 2000-2020. Men were included if they were active users of the VA system (≥2 encounters with a VA provider within a 5-yr period from 2000-2020), their age at Dx was 40> and <80 yrs, and they had no prior malignancy. Competing risks (CR) models and cumulative incidence estimates were used to assess the association (assoc) between MHI and time from PC Dx to receipt of DTx (radical prostatectomy (RP) or radiotherapy (RT)), with death treated as a CR. Logistic regression models were used to test the assoc between MHI and adherence to surv (≥3 PSAs within the first yr following DTx, and at least 1 PSA in each yr to follow for the next 4 consecutive yrs) among treated men. CR models were used to assess the assoc between MHI and time from DTx to BCR (1 PSA >0.2 ng/mL, 2 PSA ≥0.2 ng/mL, or secondary Tx for elevated PSA for RP patients (pts), and a rise of ≥2 ng/mL or more above nadir after RT) among treated men.
Results: 52,407 men diagnosed with PC (n=19,976 with MHI) were included. The cumulative incidence of DTx was higher for MHI vs non-MHI men (36% vs. 27% after 10 yrs). Men with pre-existing MHI were significantly more likely to receive DTx for PC than men without MHI in both univariable (UVA) (HR: 1.37, 95% CI: 1.32-1.41) and multivariable (MVA) (HR: 1.34, 95% CI: 1.30-1.39) analysis. Among men treated for PC (n=10,086), a similar proportion of MHI men met criteria for adhering to surv as non-MHI men (45% vs. 46%). The odds of adhering to surv did not differ significantly between MHI vs non-MHI men in UVA (OR: 0.96, 95% CI: 0.89-1.04); however, in MVA, the odds of adhering were lower in MHI vs non-MHI men (OR: 0.92, 95% CI: 0.85-1.00, p=0.049). The cumulative incidence of BCR following DTx was higher in MHI vs non-MHI men (31% vs. 28% after 15 yrs). The risk of BCR was significantly higher in MHI vs. non-MHI men in both UVA (HR: 1.08, 95% CI: 1.01, 1.15) and MVA (HR:1.07, 95% CI: 1.00-1.14).
Conclusions:
Men with MHI prior to PC Dx are more likely to receive DTx compared to non-MHI men with PC. Given that men with MHI and PC have more aggressive disease than non-MHI men with PC, more DTx is encouraging, however poorer post-Tx surv adherence and increased risk of BCR presents an opportunity for intervention to improve outcomes in these pts.
- Zachary Klaassen, Wellstar MCG Health/Georgia Cancer Center, Augusta, GA
- Jessica L. Janes, Durham VA Health Care System, Durham, NC
- Joshua Parrish, Durham Veterans Affairs Health Care System, Department of Surgery, Durham, NC
- Sydney McIntire, Durham Veterans Affairs Health Care System, Department of Surgery, Durham, NC
- Rashid K. Sayyid, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
- Nathan Taylor, Wellstar MCG Health, Augusta, GA
- Amanda Marie De Hoedt, Durham Veterans Affairs Health Care System, Department of Surgery, Durham, NC
- Stephen B. Williams, University of Texas Medical Branch at Galveston, Galveston, TX
- Martha K. Terris, Wellstar MCG Health/Georgia Cancer Center, Augusta, GA
- Stephen J. Freedland, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Durham VA Medical Center, Los Angeles, CA